Description
+ Include: 13 videos + 14 pdfs, size: 1.04 GB
+ Target Audience: oncologist
+ Sample video: contact me for sample video
+ Information:
- Start date: 15 Sep 2023
- End date: 16 Sep 2023
- Location: Barcelona, Spain
Learning objectives
- To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
- To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
- To discuss the role of locoregional therapy for cholangiocarcinoma
- To investigate the role of immunotherapy for the management of cholangiocarcinoma
- To explore currently available and novel targeted therapies and treatment options for advanced disease
+ Topics:
ESMO-Advanced-Course-on-Cholangiocarcinoma-Where-Are-We-Going-2023-Barcelona-Programme.pdf
Session 1 Patient Perspective What Should the Oncologist Treating Cholangiocarcinoma Take into Account.mp4
Session 1 Patient Perspective What Should the Oncologist Treating Cholangiocarcinoma Take into Account.pdf
Session 1 Symptom Management When Treating Patients with Cholangiocarcinoma.mp4
Session 1 Symptom Management When Treating Patients with Cholangiocarcinoma.pdf
Session 1 What is Cholangiocarcinoma (Primary Site, Molecular Biology, Epidemiology).mp4
Session 1 What is Cholangiocarcinoma (Primary Site, Molecular Biology, Epidemiology).pdf
Session 2 Adjuvant Treatment Is Capecitabine the Standard of Care.mp4
Session 2 Adjuvant Treatment Is Capecitabine the Standard of Care.pdf
Session 2 Neoadjuvant Treatment Is Perioperative Treatment Coming or Could it Have a Role.mp4
Session 2 Neoadjuvant Treatment Is Perioperative Treatment Coming or Could it Have a Role.pdf
Session 3 Locoregional Therapies How Can we Improve the Study Design.mp4
Session 3 Locoregional Therapies How Can we Improve the Study Design.pdf
Session 4 Chemotherapy First Line and Second Line. How is the Field Moving Forward.mp4
Session 4 Chemotherapy First Line and Second Line. How is the Field Moving Forward.pdf
Session 4 Immunotherapy Rationale, Current Data and Upcoming Studies.mp4
Session 4 Immunotherapy Rationale, Current Data and Upcoming Studies.pdf
Session 5 Ongoing Clinical Trials – Ongoing and Soon-to-Come Phase II and Phase III To Which Trials Shall I Recruit my Patients.mp4
Session 5 Ongoing Clinical Trials – Ongoing and Soon-to-Come Phase II and Phase III To Which Trials Shall I Recruit my Patients.pdf
Session 5 Targeted Therapies Beyond FGFR and IDH Current Data and Compounds in Advanced (Phase II and Beyond) Stage of Development.mp4
Session 5 Targeted Therapies Beyond FGFR and IDH Current Data and Compounds in Advanced (Phase II and Beyond) Stage of Development.pdf
Session 5 Targeted Therapies FGFR and IDH Current Data and Compounds in Advanced (Phase II and Beyond) Stage of Development.mp4
Session 5 Targeted Therapies FGFR and IDH Current Data and Compounds in Advanced (Phase II and Beyond) Stage of Development.pdf
Session 5 What is Coming – Phase I Input – Novel IO Strategies, Cell Therapy New Compounds in Phase I with Potential Activity.mp4
Session 5 What is Coming – Phase I Input – Novel IO Strategies, Cell Therapy New Compounds in Phase I with Potential Activity.pdf
Welcome and Introduction.mp4
Welcome and Introduction.pdf
Reviews
There are no reviews yet.